MA43250A - Composés d'oxadiazaspiro pour le traitement de l'abus et la dépendance aux drogues - Google Patents
Composés d'oxadiazaspiro pour le traitement de l'abus et la dépendance aux droguesInfo
- Publication number
- MA43250A MA43250A MA043250A MA43250A MA43250A MA 43250 A MA43250 A MA 43250A MA 043250 A MA043250 A MA 043250A MA 43250 A MA43250 A MA 43250A MA 43250 A MA43250 A MA 43250A
- Authority
- MA
- Morocco
- Prior art keywords
- addiction
- treatment
- drug abuse
- oxadiazaspiro
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Addiction (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15382566 | 2015-11-16 | ||
PCT/EP2016/001907 WO2017084752A1 (fr) | 2015-11-16 | 2016-11-15 | Composés oxadiazaspiro pour le traitement de l'abus de drogues et de la toxicomanie |
Publications (2)
Publication Number | Publication Date |
---|---|
MA43250A true MA43250A (fr) | 2021-04-14 |
MA43250B1 MA43250B1 (fr) | 2022-12-30 |
Family
ID=54707728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA43250A MA43250B1 (fr) | 2015-11-16 | 2016-11-15 | Composés d'oxadiazaspiro pour le traitement de l'abus et la dépendance aux drogues |
Country Status (30)
Country | Link |
---|---|
US (2) | US10927128B2 (fr) |
EP (1) | EP3377500B1 (fr) |
JP (1) | JP6884974B2 (fr) |
KR (1) | KR20180080327A (fr) |
CN (1) | CN108349999A (fr) |
AR (1) | AR106697A1 (fr) |
AU (1) | AU2016356488B2 (fr) |
BR (1) | BR112018009279A8 (fr) |
CA (1) | CA3002286A1 (fr) |
CO (1) | CO2018004665A2 (fr) |
DK (1) | DK3377500T3 (fr) |
ES (1) | ES2932000T3 (fr) |
HR (1) | HRP20221343T1 (fr) |
HU (1) | HUE060275T2 (fr) |
IL (1) | IL259035B (fr) |
LT (1) | LT3377500T (fr) |
MA (1) | MA43250B1 (fr) |
MX (1) | MX2018005439A (fr) |
MY (1) | MY193423A (fr) |
PH (1) | PH12018500814A1 (fr) |
PL (1) | PL3377500T3 (fr) |
PT (1) | PT3377500T (fr) |
RS (1) | RS63734B1 (fr) |
SG (1) | SG11201803153RA (fr) |
SI (1) | SI3377500T1 (fr) |
TN (1) | TN2018000122A1 (fr) |
TW (1) | TWI756196B (fr) |
UA (1) | UA123775C2 (fr) |
WO (1) | WO2017084752A1 (fr) |
ZA (1) | ZA201802845B (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI756196B (zh) | 2015-11-16 | 2022-03-01 | 西班牙商艾斯提夫製藥股份有限公司 | 用於治療藥物濫用和成癮之氧雜二氮雜螺環化合物 |
WO2020157026A1 (fr) * | 2019-01-28 | 2020-08-06 | Esteve Pharmaceuticals, S.A. | Dérivés hydroxylés de composés de 1-oxa-4,9-diazaspiro-undécane ayant une activité multimodale contre la douleur |
AU2022346825A1 (en) | 2021-09-20 | 2024-03-07 | Esteve Pharmaceuticals, S.A. | Oxadiazaspiro compounds for use in the treatment of motoneuron degeneration or in neuroprotection |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4244961A (en) * | 1978-10-26 | 1981-01-13 | Syntex (U.S.A.) Inc. | 1-Oxa-3,8-diazaspiro[4.5]decan-2-ones antihypertensive agents |
US4332804A (en) | 1981-03-23 | 1982-06-01 | Syntex (U.S.A.) Inc. | 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones |
US4353901A (en) * | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones |
US4353900A (en) | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones |
US6114541A (en) | 1997-03-10 | 2000-09-05 | Hoffmann-La Roche Inc. | Method for the preparation of α-Bromo-Lactam derivatives |
CA2554671A1 (fr) * | 2004-02-10 | 2005-08-18 | F.Hoffmann-La Roche Ag | Modulateurs des recepteurs ccr5 de chimiokine |
DE602005025979D1 (de) | 2004-03-03 | 2011-03-03 | Vital Health Sciences Pty Ltd | Alkaloid-formulierungen |
EP1634873A1 (fr) | 2004-08-27 | 2006-03-15 | Laboratorios Del Dr. Esteve, S.A. | Inhibiteurs des récepteurs sigma |
JP5135795B2 (ja) * | 2004-08-27 | 2013-02-06 | 小野薬品工業株式会社 | 塩基性基を含有する化合物およびその用途 |
CN101228127B (zh) | 2005-05-30 | 2012-05-16 | Msdk.K.公司 | 哌啶衍生物 |
CN101203567A (zh) * | 2005-06-07 | 2008-06-18 | 西巴特殊化学品控股有限公司 | 抗刮擦聚烯烃 |
DE102005030051A1 (de) | 2005-06-27 | 2006-12-28 | Grünenthal GmbH | Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
JP5323485B2 (ja) | 2005-10-19 | 2013-10-23 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 新規バニロイド受容体リガンド及医薬の製造へのその使用 |
PT1961744E (pt) | 2005-11-18 | 2013-05-15 | Ono Pharmaceutical Co | Composto que contém um grupo básico e sua utilização |
EP1829869A1 (fr) | 2006-03-02 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | Dérivés de 4,5,6,7-tétrahydrobenzo[b]thiophène et leur utilisaton comme ligands du récepteur sigma |
EP1847542A1 (fr) | 2006-04-21 | 2007-10-24 | Laboratorios del Dr. Esteve S.A. | Dérivés de spiro[benzopyran] ou de spiro[benzofuran] comme antagonistes du récepteur sigma |
AU2008219980B2 (en) | 2007-03-01 | 2012-01-12 | Mitsubishi Tanabe Pharma Corporation | Benzimidazole compound and pharmaceutical use thereof |
EP1982714A1 (fr) | 2007-04-16 | 2008-10-22 | Laboratorios del Dr. Esteve S.A. | Pyrano-pyrazole-aminés |
EP2020414A1 (fr) | 2007-06-20 | 2009-02-04 | Laboratorios del Dr. Esteve S.A. | Derivés spiro[piperidine-4,4'-thieno[3,2-c]pyran] et composés similaires en tant que inhibiteurs du recepteur sigma pour le traitement de pyschose |
JP2010538003A (ja) | 2007-08-29 | 2010-12-09 | グラクソスミスクライン エルエルシー | チアゾールおよびオキサゾールキナーゼ阻害薬 |
EP2070933A1 (fr) | 2007-12-07 | 2009-06-17 | Laboratorios del Dr. Esteve S.A. | Composants triazoliques tricycliques |
ES2394547T3 (es) | 2008-02-06 | 2013-02-01 | Astrazeneca Ab | Compuestos |
EP2108643A1 (fr) * | 2008-04-10 | 2009-10-14 | Laboratorios Del. Dr. Esteve, S.A. | 4-Méthyl-4, 5-dihydro-1H-pyrazole-3-carboxamide utile en tant qu'antagoniste neutre de cannabinoïde CB1 |
GB201016912D0 (en) * | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
CN103517910B (zh) | 2011-03-14 | 2016-12-14 | 沃泰克斯药物股份有限公司 | 作为离子通道调节剂的吗啉-螺环哌啶酰胺 |
GB201107985D0 (en) | 2011-05-13 | 2011-06-29 | Astrazeneca Ab | Process |
WO2013052716A1 (fr) * | 2011-10-07 | 2013-04-11 | Glaxosmithkline Llc | Inhibiteurs de l'acide gras synthase |
JPWO2013115294A1 (ja) | 2012-01-31 | 2015-05-11 | 東レ株式会社 | ジアザスピロウレア誘導体及びその医薬用途 |
US9751881B2 (en) | 2013-07-31 | 2017-09-05 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
TW201615642A (zh) | 2014-06-02 | 2016-05-01 | 伊史帝夫博士實驗室股份有限公司 | 具有多重模式抗疼痛活性的1-氧雜-4,9-二氮雜螺十一烷化合物之醯胺衍生物 |
TWI685497B (zh) * | 2014-06-02 | 2020-02-21 | 西班牙商伊史帝夫製藥公司 | 具有多重模式抗疼痛活性的1-氧雜-4,9-二氮雜螺十一烷化合物之烷基衍生物 |
TW201615643A (zh) * | 2014-06-02 | 2016-05-01 | 伊史帝夫博士實驗室股份有限公司 | 具有多重模式抗疼痛活性之1-氧雜-4,9-二氮雜螺十一烷化合物之烷基與芳基衍生物 |
US10513518B2 (en) * | 2015-01-29 | 2019-12-24 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
TWI756196B (zh) | 2015-11-16 | 2022-03-01 | 西班牙商艾斯提夫製藥股份有限公司 | 用於治療藥物濫用和成癮之氧雜二氮雜螺環化合物 |
-
2016
- 2016-11-15 TW TW105137236A patent/TWI756196B/zh active
- 2016-11-15 AU AU2016356488A patent/AU2016356488B2/en active Active
- 2016-11-15 CA CA3002286A patent/CA3002286A1/fr active Pending
- 2016-11-15 JP JP2018524257A patent/JP6884974B2/ja active Active
- 2016-11-15 EP EP16797458.3A patent/EP3377500B1/fr active Active
- 2016-11-15 PL PL16797458.3T patent/PL3377500T3/pl unknown
- 2016-11-15 HR HRP20221343TT patent/HRP20221343T1/hr unknown
- 2016-11-15 KR KR1020187017092A patent/KR20180080327A/ko not_active Application Discontinuation
- 2016-11-15 SI SI201631621T patent/SI3377500T1/sl unknown
- 2016-11-15 MY MYPI2018701503A patent/MY193423A/en unknown
- 2016-11-15 RS RS20221052A patent/RS63734B1/sr unknown
- 2016-11-15 DK DK16797458.3T patent/DK3377500T3/da active
- 2016-11-15 ES ES16797458T patent/ES2932000T3/es active Active
- 2016-11-15 SG SG11201803153RA patent/SG11201803153RA/en unknown
- 2016-11-15 HU HUE16797458A patent/HUE060275T2/hu unknown
- 2016-11-15 MX MX2018005439A patent/MX2018005439A/es unknown
- 2016-11-15 UA UAA201806353A patent/UA123775C2/uk unknown
- 2016-11-15 LT LTEPPCT/EP2016/001907T patent/LT3377500T/lt unknown
- 2016-11-15 WO PCT/EP2016/001907 patent/WO2017084752A1/fr active Application Filing
- 2016-11-15 BR BR112018009279A patent/BR112018009279A8/pt active IP Right Grant
- 2016-11-15 MA MA43250A patent/MA43250B1/fr unknown
- 2016-11-15 PT PT167974583T patent/PT3377500T/pt unknown
- 2016-11-15 TN TNP/2018/000122A patent/TN2018000122A1/en unknown
- 2016-11-15 AR ARP160103486A patent/AR106697A1/es unknown
- 2016-11-15 US US15/774,407 patent/US10927128B2/en active Active
- 2016-11-15 CN CN201680066748.9A patent/CN108349999A/zh active Pending
-
2018
- 2018-04-16 PH PH12018500814A patent/PH12018500814A1/en unknown
- 2018-04-30 ZA ZA2018/02845A patent/ZA201802845B/en unknown
- 2018-04-30 IL IL259035A patent/IL259035B/en active IP Right Grant
- 2018-04-30 CO CONC2018/0004665A patent/CO2018004665A2/es unknown
-
2020
- 2020-12-21 US US17/128,738 patent/US11649248B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
MA46791A (fr) | Composés et procédés pour réduire l'expression d'atxn3 | |
MA44083A (fr) | Composés de biarylmonobactame pour le traitement d'infections bactériennes | |
MA40008A (fr) | Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie | |
MA39960A (fr) | Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer | |
MA42439A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
MA40867A (fr) | Méthodes pour le traitement d'infections virales à filoviridae | |
MA41449A (fr) | Polythérapies pour le traitement de cancers | |
MA46836A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
MA47719A (fr) | Esketamine pour le traitement de la dépression | |
MA52308A (fr) | Procédés et intermédiaires pour la préparation d'antagonistes c5ar | |
MA52253A (fr) | Formulation de poudre nasale pour le traitement de l'hypoglycémie | |
IL290754A (en) | Use of pyridofidine to treat anxiety and depression | |
MA46892A (fr) | Composés d'alcène tétrasubstitués et leur utilisation pour le traitement du cancer du sein | |
MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
MA46896A (fr) | Composés d'alcène tétrasubstitués et leur utilisation | |
FR3013184B1 (fr) | Utilisation d'hydroxyapatite pour le traitement de l'esca | |
MA43825A (fr) | Schémas posologiques pour le traitement d'infections fongiques | |
MA46099A (fr) | Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial | |
HK1257584A1 (zh) | 預防和治療系統性硬化症的藥物及其用途 | |
MA41629A (fr) | Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité | |
MA46431A (fr) | Composés et procédés pour réduire l'expression de tau | |
MA43250A (fr) | Composés d'oxadiazaspiro pour le traitement de l'abus et la dépendance aux drogues | |
FR3020951B1 (fr) | Association d'un tetrapeptide et d'un glyceryl ester pour le traitement de l'alopecie androgenique. |